Antibacterial and antifungal action of CTAB-containing silica nanoparticles against human pathogens

Antibacterial and antifungal action of CTAB-containing silica nanoparticles against human pathogens

[Display omitted] New antibiotic agents are urgently needed worldwide to combat the increasing tolerance and resistance of pathogenic fungi and bacteria to current antimicrobials. Here, we looked at the antibacterial and antifungal effects of minor quantities of cetyltrimethylammonium bromide (CTAB)...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics Vol. 641; p. 123074
Main Authors: Martins da Silva Filho, Pedro, Higor Rocha Mariano, Pedro, Lopes Andrade, Alexandre, Barros Arrais Cruz Lopes, Jessica, de Azevedo Pinheiro, Aryane, Itala Geronimo de Azevedo, Mayara, Carneiro de Medeiros, Suelen, Alves de Vasconcelos, Mayron, Gonçalvez da Cruz Fonseca, Said, Barbosa Grangeiro, Thalles, Gonzaga de França Lopes, Luiz, Henrique Silva Sousa, Eduardo, Holanda Teixeira, Edson, Longhinotti, Elisane
Format: Journal Article
Language:English
Published: Netherlands Elsevier B.V 25-06-2023
Subjects:
Anti-Bacterial Agents - pharmacology
Antifungal Agents - pharmacology
Antimicrobial
Cetrimonium - pharmacology
Cetyltrimethylammonium bromide
Humans
Metal Nanoparticles
Methicillin-Resistant Staphylococcus aureus
Microbial Sensitivity Tests
Nanoparticles
Silica
Silicon Dioxide - pharmacology
Staphylococcus aureus
Surfactant
Synergistic action
Nanoparticles
Antimicrobial
Cetyltrimethylammonium bromide
Synergistic action
Surfactant
Silica
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] New antibiotic agents are urgently needed worldwide to combat the increasing tolerance and resistance of pathogenic fungi and bacteria to current antimicrobials. Here, we looked at the antibacterial and antifungal effects of minor quantities of cetyltrimethylammonium bromide (CTAB), ca. 93.8 mg g−1, on silica nanoparticles (MPSi-CTAB). Our results show that MPSi-CTAB exhibits antimicrobial activity against Methicillin-resistant Staphylococcus aureus strain (S. aureus ATCC 700698) with MIC and MBC of 0.625 mg mL−1 and 1.25 mg mL−1, respectively. Additionally, for Staphylococcus epidermidis ATCC 35984, MPSi-CTAB reduces MIC and MBC by 99.99% of viable cells on the biofilm. Furthermore, when combined with ampicillin or tetracycline, MPSi-CTAB exhibits reduced MIC values by 32– and 16-folds, respectively. MPSi-CTAB also exhibited in vitro antifungal activity against reference strains of Candida, with MIC values ranging from 0.0625 to 0.5 mg mL−1. This nanomaterial has low cytotoxicity in human fibroblasts, where over 80% of cells remained viable at 0.31 mg mL−1 of MPSi-CTAB. Finally, we developed a gel formulation of MPSi-CTAB, which inhibited in vitro the growth of Staphylococcus and Candida strains. Overall, these results support the efficacy of MPSi-CTAB with potential application in the treatment and/or prevention of infections caused by methicillin-resistant Staphylococcus and/or Candida species.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2023.123074